NO943915L - Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien - Google Patents

Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien

Info

Publication number
NO943915L
NO943915L NO943915A NO943915A NO943915L NO 943915 L NO943915 L NO 943915L NO 943915 A NO943915 A NO 943915A NO 943915 A NO943915 A NO 943915A NO 943915 L NO943915 L NO 943915L
Authority
NO
Norway
Prior art keywords
lymphocyte activation
activation antigen
immunoglobulin superfamily
disclosed
expressed
Prior art date
Application number
NO943915A
Other languages
English (en)
Norwegian (no)
Other versions
NO943915D0 (no
Inventor
Thomas F Tedder
Liang-Ji Zhou
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of NO943915D0 publication Critical patent/NO943915D0/no
Publication of NO943915L publication Critical patent/NO943915L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO943915A 1992-04-17 1994-10-14 Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien NO943915L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/870,029 US5316920A (en) 1992-04-17 1992-04-17 Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
PCT/US1993/003577 WO1993021318A1 (fr) 1992-04-17 1993-04-14 Antigene hb15 d'activation lymphocytaire appartenant au sous-ordre des immunoglobulines

Publications (2)

Publication Number Publication Date
NO943915D0 NO943915D0 (no) 1994-10-14
NO943915L true NO943915L (no) 1994-12-09

Family

ID=25354648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943915A NO943915L (no) 1992-04-17 1994-10-14 Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien

Country Status (10)

Country Link
US (1) US5316920A (fr)
EP (1) EP0636176B1 (fr)
JP (2) JP3973167B2 (fr)
AT (1) ATE185600T1 (fr)
AU (1) AU685745B2 (fr)
BR (1) BR9306344A (fr)
CA (1) CA2118309C (fr)
DE (1) DE69326759T2 (fr)
NO (1) NO943915L (fr)
WO (1) WO1993021318A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5534430A (en) * 1993-08-31 1996-07-09 Hitachi Chemical Company Limited Cell strain capable of multiplying an Epstein-Barr virus
AU2273397A (en) * 1996-02-15 1997-09-02 Immunex Corporation Methods and compositions for modulating an immune response
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6361939B1 (en) 1996-11-27 2002-03-26 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
AU5356498A (en) * 1996-11-27 1998-06-22 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
US6210672B1 (en) 1998-10-20 2001-04-03 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce Langerhans cell migration
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
WO2003045318A2 (fr) * 2001-11-21 2003-06-05 Celltech R & D, Inc. Manipulation de taux de cytokine au moyen de produits de gene cd83
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
EP1422241A1 (fr) * 2002-11-19 2004-05-26 Alexander Steinkasserer Utilisation des formes solubles des CD83 et acides nucleiques les codant dans letraitement et la prevention des maladies
EP1572976B1 (fr) * 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulation de reponses immunitaires
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
WO2008024242A2 (fr) 2006-08-18 2008-02-28 Argos Therapeutics, Inc. Utilisation de cd83 dans des polythérapies
ES2397112T3 (es) 2007-06-15 2013-03-04 Panasonic Corporation Aparato de comunicación inalámbrica y procedimiento de difusión de señal de respuesta
CN102036690B (zh) * 2008-05-23 2013-11-06 阿哥斯医疗公司 新型可溶性cd83多肽、制剂及使用方法
MX2015010023A (es) 2013-02-01 2017-11-17 Transbio Ltd Anticuerpos anti-cd83 y su uso.
NZ731491A (en) 2014-10-23 2021-12-24 Kira Biotech Pty Ltd Cd83 binding proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010321C (fr) * 1989-02-21 2004-04-06 Thomas F. Tedder Proteine de surface de cellules associees aux lymphocytes
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
WO1992001049A2 (fr) * 1990-07-13 1992-01-23 The General Hospital Corporation Antigene de surface de cellule cd53 et son utilisation

Also Published As

Publication number Publication date
US5316920A (en) 1994-05-31
DE69326759D1 (de) 1999-11-18
DE69326759T2 (de) 2000-03-02
BR9306344A (pt) 1998-06-30
WO1993021318A1 (fr) 1993-10-28
JP2007159580A (ja) 2007-06-28
CA2118309C (fr) 2000-06-13
AU685745B2 (en) 1998-01-29
EP0636176A1 (fr) 1995-02-01
ATE185600T1 (de) 1999-10-15
CA2118309A1 (fr) 1993-10-28
JPH09508781A (ja) 1997-09-09
EP0636176B1 (fr) 1999-10-13
NO943915D0 (no) 1994-10-14
AU4104893A (en) 1993-11-18
JP3973167B2 (ja) 2007-09-12

Similar Documents

Publication Publication Date Title
NO943915L (no) Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien
Germann et al. Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
Vercelli et al. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens.
Seeley et al. Studies on Cytotoxicity Generated in Human Mixed Lymphocyte Cultures: II. Anti-K562 Effectors Are Distinct from Allospecific CTL and Can Be Generated from NK-Depleted T Cells
EP1329459A3 (fr) Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
DK0489837T3 (da) Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand
Klaus et al. A re-evaluation of the role of C3 in B-cell activation
EP1003552A4 (fr) ANTICORPS DIRIGE CONTRE LO-CD2a ET UTILISATION DE CELUI-CI POUR INHIBER L'ACTIVATION ET LA PROLIFERATION DES LYMPHOCYTES T
EP0674661A4 (fr) Titrage et traitement destines aux maladies demyelinisantes telles que la sclerose en plaques.
McInnes et al. New strategies to control inflammatory synovitis: interleukin 15 and beyond
Schwab et al. Defective expression of high affinity IL-2 receptors on activated T cells from aged humans
Samberg et al. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes
Heusser et al. New concepts of IgE regulation
Hodge et al. Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF‐beta as an immunomodulatory component in plasma‐derived factor VIII concentrate
De Weck et al. New perspectives in the modulation of allergic inflammation
Pollack et al. Inhibition of antibody-dependent cellular cytotoxicity by autologous lymph node cells
Poros et al. Expression of Helix pomatia (HP) haemagglutinin receptors on cytolytic lymphocytes activated in mixed cultures
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
Mosmann et al. Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones
Gorczynski et al. Individual‐specific (idiotypic) T‐B cell interactions regulating the production of anti‐2, 4, 6‐trinitrophenyl antibody. I. Generation of suppressor T cells and antibody directed against immunocompetent cells
Trail Canine T lymphocyte subpopulations defined by the expression of IgMFc and IgGFc receptors: factors influencing Fc receptor expression and alterations in T lymphocyte subpopulations in two models of canine disease.
Morito et al. Complement split products C3d in plasma from patients with systemic lupus erythematosus
Tominaga et al. Effects of IL-5 on the expression of adhesion molecules on eosinophils